+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human gastric cancer tissue using P08060(PDCD1LG2 Antibody) at dilution 1/50. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P08060(PDCD1LG2 Antibody) at dilution 1/50. (Original magnification: ×200)    

  
  

The PDCD1LG2 antibody targets PDCD1LG2 (Programmed Cell Death 1 Ligand 2), also known as PD-L2. a cell surface protein belonging to the B7 family of immune checkpoint molecules. PD-L2 binds to the PD-1 receptor on T cells, delivering inhibitory signals that suppress T-cell activation and promote immune tolerance. While structurally similar to PD-L1 (PDCD1L1), PD-L2 exhibits a more restricted expression pattern, primarily found on antigen-presenting cells (e.g., dendritic cells, macrophages) and some tumor cells. Its role in immune evasion has made it a focus in cancer immunotherapy research.

PDCD1LG2 antibodies are designed to block PD-L2/PD-1 interactions, potentially restoring T-cell-mediated antitumor immunity. However, therapeutic interest in PD-L2 has been less prominent compared to PD-L1. partly due to its narrower expression and overlapping functions with PD-L1. Recent studies suggest PD-L2 may have distinct roles in specific cancers or immune contexts, such as modulating Th2 responses or influencing resistance to PD-1/PD-L1 inhibitors. Research tools like PDCD1LG2 antibodies are critical for elucidating its biology, while therapeutic antibodies remain exploratory, with some in preclinical development. Understanding PD-L2's dual roles—both as an immune checkpoint and a regulator of tissue homeostasis—could uncover new avenues for combination therapies or biomarkers in oncology and autoimmune diseases.